NL-OMON21711尚未招募不适用
A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme: the STELLAR study
VU University Medical Center0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Signed (by the patient or legally acceptable representative) and dated Informed Consent Form
- •2.Histologically confirmed de novo or secondary glioblastoma with unequivocal first progression, at least 3 months off radiotherapy.
排除标准
- •1.Evidence of a significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); nervous system, pulmonary (including obstructive pulmonary disease and history of symptomatic bronchospasm), renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture.
- •2.Patients with a prior (< 5 years) or concomitant second malignancy.
研究者
相似试验
进行中（未招募）
1 期
A trial testing an alternative high-dose, intermittend scheduling for sunitinib in patients with recurrent brain cancer- Glioblastoma multiforme (GBM)- GlioblastomaEUCTR2016-001797-15-NLVU University Medical Center, Department of Medical Oncology100
已完成
2 期
A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent GBMBrain cancer10029211Glioblastoma multiformeNL-OMON50728Radboud Universitair Medisch Centrum100
招募中
2 期
A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).metastatic colorectal carcinoma1001799010017991NL-OMON53126Radboud Universitair Medisch Centrum70
招募中
不适用
A randomized phase II study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC).NL-OMON27160Radboud UMC60
已完成
不适用
A phase I study of high-dose, intermittent sunitinib in patients with solid tumorssunitinib dosing10027476NL-OMON44759Vrije Universiteit Medisch Centrum40